[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1):5-29.  doi: 10.3322/caac.21254
[2] 韩苏军, 张思维, 陈万青, 等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志, 2013, 18(4):330-334.  doi: 10.3969/j.issn.1009-0460.2013.04.009
[3]

赫捷, 陈万青. 2012中国肿瘤登记年报[M].北京:军事医学科学出版社, 2012.
[4] Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol, 2012, 61(6):1079-1092.  doi: 10.1016/j.eururo.2012.02.054
[5] Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant Prostate Cancer:From New Pathophysiology to New Treatment Targets[J]. Eur Urol, 2009, 56(4):594-605.
[6] Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1:screening, diagnosis, and treatment of clinically localised disease[J]. Eur Urol, 2011, 59(1):61-71.
[7] Chin JL, Srigley J, Mayhew LA, et al. Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management:evidentiary base[J]. Can Urol Assoc J, 2010, 4(1):13-25.  doi: 10.5489/cuaj.08105
[8] Sgouros G, Roeske JC, McDevitt MR, et al. MIRD pamphlet No. 22(abridged):radiobiology and dosimetry of alpha-Particle emitters for targeted radionuclide therapy[J]. J Nucl Med, 2010, 51(2):311-328.  doi: 10.2967/jnumed.108.058651
[9] Pandit-Taskar N, Larson SM, Carrasquillo JA. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1:α therapy with 223Ra-dichloride[J]. J Nucl Med, 2014, 55(2):268-274.
[10] Henriksen G, Breistøl K, Bruland ØS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model[J]. Cancer Res, 2002, 62(11):3120-3125.
[11] Hobbs RF, Song H, Watchman CJ, et al. A bone marrow toxicity model for Ra-223 alpha-emitter radiopharmaceutical therapy[J]. Phys Med Biol, 2012, 57(10):3207-3222.  doi: 10.1088/0031-9155/57/10/3207
[12] Neuman WF, Hursh JB, Boyd J, et al. On the mechanism of skeletal fixation of radium[J]. Ann N Y Acad Sci, 1955, 62(6):125-136.  doi: 10.1111/j.1749-6632.1955.tb35369.x
[13] Parker C, Heinrich D, O′sullivan JM, et al. Overall survival benefit of radium-223 chloride(Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer(CRPC):a phase Ⅲ randomized trial(ALSYMPCA)[Abstract 1LBA][J]. Eur J Cancer, 2011, 47(suppl 2):3.
[14] Kluetz PG, Pierce W, Maher VE, et al. Radium Ra 223 dichloride injection:U. S. food and Drug Administration drug approval summary[J]. Clin Cancer Res, 2014, 20(1):9-14.  doi: 10.1158/1078-0432.CCR-13-2665
[15] Nilsson S, Larsen RH, Fossả SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases[J]. Clin Cancer Res, 2005, 11(12):4451-4459.  doi: 10.1158/1078-0432.CCR-04-2244
[16] Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer:a randomised, multicentre, placebo-controlled phase Ⅱ study[J]. Lancet Oncol, 2007, 8(7):587-594.  doi: 10.1016/S1470-2045(07)70147-X
[17] Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase Ⅱ study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer[J]. Eur J Cancer, 2012, 48(5):678-686.  doi: 10.1016/j.ejca.2011.12.023
[18] Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. N Engl J Med, 2013, 369(3):213-223.  doi: 10.1056/NEJMoa1213755
[19] Dauer LT, Williamson MJ, Humm J, et al. Radiation safety considerations for the use of 223RaCl DE in men with castration-resistant prostate cancer[J]. Health Phys, 2014, 106(4):494-504.  doi: 10.1097/HP.0b013e3182a82b37
[20] Coleman R, Aksnes AK, Naume B, et al. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease[J]. Breast Cancer Res Treat, 2014, 145(2):411-418.  doi: 10.1007/s10549-014-2939-1
[21] Takalkar A, Adams S, Subbiah V. Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone[J]. Exp Hematol Oncol, 2014, 3:23.  doi: 10.1186/2162-3619-3-23
[22]

Algeta ASA. A study of Alpharadin with docetaxel in patients with bone metastasis from castration-resistant prostate cancer(CRPC)[DB/OL]. US National Institutes of Health, ClinicalTrials. gov, 2012[2015-01-12]. http://www.clinicaltrials.gov/ct2/show/NCT01106352.
[23] Clark MJ, Harris N, Griebsch I, et al. Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union[J]. Health Qual Life Outcomes, 2014, 12:104.  doi: 10.1186/s12955-014-0104-5
[24] Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer:results of a phase 3, randomised, placebo-controlled trial[J]. Lancet, 2012, 379(9810):39-46.  doi: 10.1016/S0140-6736(11)61226-9
[25] Cheever MA, Higano CS. PROVENGE(Sipuleucel-T) in prostate cancer:the first FDA-approved therapeutic cancer vaccine[J]. Clin Cancer Res, 2011, 17(11):3520-3526.  doi: 10.1158/1078-0432.CCR-10-3126